2篇
您的检索式：作者名="Chrystal M.Paulos"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | When worlds collide: Th17 and Treg cells in cancer and autoimmunity显示文摘The balance between Th17 cells and regulatory T cells(Tregs)has emerged as a prominent factor in regulating autoimmunity and cancer.Th17 cells are vital for host defense against pathogens but have also been implicated in causing autoimmune disorders and cancer,though their role in carcinogenesis is less well understood.Tregs are required for self-tolerance and defense against autoimmunity and often correlate with cancer progression.This review addresses the importance of a functional homeostasis between these two subsets in health and the consequences of its disruption when these forces collide in disease.Importantly,we discuss the ability of Th17 cells to mediate cancer regression in immunotherapy,including adoptive transfer and checkpoint blockade therapy,and the therapeutic possibilities of purposefully offsetting the Th17/Treg balance to treat patients with cancer as well as those with autoimmune diseases. | Hannah M.Knochelmann Connor J.Dwyer Stefanie R.Bailey Sierra M.Amaya Dirk M.Elston Joni M.Mazza-Mc.Crann Chrystal M.Paulos | 2018 | Cellular & Molecular Immunology2018，15，5： | 50 |
| 2 | Programmed death 1 (PD-1) and ligand (PD-L1) inhibitors in head and neck squamous cell carcinoma: A meta-analysis显示文摘Background: PD-1 and PD-L1 inhibitors have emerged as promising treatments for patients with head and neck squamous cell carcinoma (HNSCC).Methods: Systematic review and meta-analysis of PD-1 and PD-L1 inhibitors in HNSCC. Outcomes: median overall survival (mOS), median progression-free survival (mPFS), Response Evaluation Criteria in Solid Tumors (RECIST) and treatment-related adverse events (TRAEs).Results: Eleven trials reported data on 1088 patients (mean age: 59.9 years, range: 18-90). The total mOS was 7.97 months (range: 6.0-16.5). Mean mPFS for all studies was 2.84 months (range: 1.9-6.5). PD-1 inhibitors had a lower rate of RECIST Progressive Disease than PD-L1 inhibitors (42.61%, 95% confidence interval [CI]: 36.29-49.06 vs. 56.79%, 95% CI: 49.18-64.19,P < 0.001). The rate of TRAEs of any grade (62.7%, 95% CI: 59.8-65.6) did not differ.Conclusions: Meta-analysis shows the efficacy of PD-1 and PD-L1 inhibitors in HNSCC and suggests a possible difference in certain RECIST criterion between PD-1 and PD-L1 inhibitors. Future work to investigate the clinical significance of these findings is warranted. | Dylan A.Levy Jaimin J.Patel Shaun A.Nguyen W.Nicholas Jungbauer David M.Neskey Ezra E.W.Cohen Chrystal M.Paulos John A.Kaczmar Hannah M.Knochelmann Terry A.Day | 2022 | World Journal of Otorhinolaryngology-Head and Neck Surgery2022，8，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员